LFMD vs PDEX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LFMD exhibits severe financial deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic Q/Q revenue decline of 88.98%. While the company maintains a low debt-to-equity ratio, the combination of negative operating margins, a deeply negative ROE (-131.16%), and a 0/4 earnings beat record over the last four quarters indicates a business in crisis. Despite a high analyst target price of $9.88, the fundamental data and technical trend (0/100) suggest a value trap scenario.
PDEX exhibits a stable financial profile with a Piotroski F-Score of 6/9 and a strong balance sheet characterized by low leverage and high liquidity. While the current price of $52.60 is above the defensive Graham Number ($31.55), it remains well below the growth-based intrinsic value of $65.81. The company demonstrates exceptional capital efficiency with an ROE of 30.87% and a very healthy current ratio of 4.03. Despite a bearish technical trend indicator, the fundamental growth and profitability metrics suggest significant underlying strength.
Compare Another Pair
Related Comparisons
LFMD vs PDEX: Head-to-Head Comparison
This page compares LifeMD, Inc. (LFMD) and Pro-Dex, Inc. (PDEX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.